1995 Results

People

  1. Kris
    Kris
  2. Motzer
    Motzer
  3. Scher
    Scher
  4. Saltz
    Saltz
  5. Schwartz
    Schwartz
  6. Hudis
    Hudis
  7. Kelsen
    Kelsen
  8. Rosen
    Rosen
  9. Marks
    Marks
  10. De Angelis
    De Angelis

Groups

  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)
  7. Sloan Kettering Institute Faculty (227)
  8. Hematologic Malignancies, Division of (224)
  9. Genitourinary Oncology Service (203)
  10. Molecular Pharmacology and Chemistry Program Faculty (172)
  1. "antineoplastic agents"
Formats
  1. Journal Article (1901)
  2. Review (47)
  3. Conference Paper (23)
  4. Editorial (7)
  5. Research Letter (6)
  6. Guidelines (4)
  7. Book Section (3)
  8. Correspondence (2)
  9. Meeting Abstract (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (969)
  2. Solid Tumor Oncology Division (729)
  3. Surgery (289)
  4. GSK Faculty (287)
  5. Survivorship Research (260)
  6. Center for Hematologic Malignancies (230)

More Groups

People
  1. Mark Kris (77)
  2. Robert Motzer (70)
  3. Howard Scher (58)
  4. Gary Schwartz (52)
  5. Leonard Saltz (52)
  6. Ting-Chao Chou (50)

More People

Years
  1. 2025 (16)
  2. 2024 (65)
  3. 2023 (49)
  4. 2022 (49)
  5. 2021 (11)
  6. 2020 (4)

More Years

Publications
  1. Clinical Cancer Research (114)
  2. Journal of Clinical Oncology (111)
  3. Cancer (70)
  4. Seminars in Oncology (51)
  5. New England Journal of Medicine (43)
  6. Cancer Research (40)

More Publications

Publishers
  1. Elsevier Inc. (240)
  2. American Association for Cancer Research (187)
  3. Springer (175)
  4. American Society of Clinical Oncology (129)
  5. Wiley Blackwell (112)
  6. Nature Publishing Group (92)

More Publishers

Results (1995)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of ginger on the side effects of chemotherapy in breast cancer patients: Systematic review and meta-analysis
    Review

    Kim, S. D.; Kwag, E. B.; Yang, M. X.; Yoo, H. S.
    International Journal of Molecular Sciences (2022)

    Fulltext@MSK | Save
  • HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
    Review

    Tabernero, J.; Shen, L.; Elimova, E.; Ku, G.; Liu, T.; Shitara, K.; Lin, X.; Boyken, L.; Li, H.; Grim, J.; more...
    Future Oncology (2022)

    Fulltext@MSK | Save
  • Phase III MANIFEST-2: Pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
    Review

    Harrison, C. N.; Gupta, V. K.; Gerds, A. T.; Rampal, R.; Verstovsek, S.; Talpaz, M.; Kiladjian, J. J.; Mesa, R.; Kuykendall, A. T.; Vannucchi, A. M.; more...
    Future Oncology (2022)

    Fulltext@MSK | Save
  • Synthesis of carbohydrate analogues of the THF-acetogenin 4-deoxyannomontacin and their cytotoxicity against human prostate cancer cell lines
    Journal Article

    Gonzalez Periche, P.; Ramdular, A.; Bhupathiraju, N. V. S. D. K.; Kalidindi, T.; Johnson, D. S.; Pillarsetty, N.; Mootoo, D. R.
    Carbohydrate Research (2022)

    Fulltext@MSK | Save
  • Five decades of sarcoma care at Memorial Sloan Kettering Cancer Center
    Review

    Brennan, M. F.; Singer, S.
    Journal of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
    Journal Article

    Borazanci, E.; Schram, A. M.; Garralda, E.; Brana, I.; Vieito Villar, M.; Spreafico, A.; Oliva, M.; Lakhani, N. J.; Hoffman, K.; Hallett, R. M.; more...
    ESMO Open (2022)

    Fulltext@MSK | Save
  • Abnormal photoplethysmography waveforms are associated with chemotherapy induced neuropathy
    Journal Article

    Bryce, Y.; Santos-Martin, E.; Ziv, E.; Gonzalez-Aguirre, A.; Moussa, A.; Friedman, A.; Maybody, M.
    Vasa - European Journal of Vascular Medicine (2022)

    Fulltext@MSK | Save
  • Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial
    Journal Article

    Padrón, L. J.; Maurer, D. M.; O’Hara, M. H.; O’Reilly, E. M.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; more...
    Nature Medicine (2022)

    Fulltext@MSK | Save
  • Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: Final results from the BFORE trial
    Journal Article

    Brümmendorf, T. H.; Cortes, J. E.; Milojkovic, D.; Gambacorti-Passerini, C.; Clark, R. E.; le Coutre, P.; Garcia-Gutierrez, V.; Chuah, C.; Kota, V.; Lipton, J. H.; more...
    Leukemia (2022)

    Fulltext@MSK | Save
  • A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase
    Review

    García-Gutiérrez, V.; Breccia, M.; Jabbour, E.; Mauro, M.; Cortes, J. E.
    Journal of Hematology & Oncology (2022)

    Fulltext@MSK | Save